News | July 23, 2025
Torrent Pharma launches nutrition supplement powder Shelcal Total
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The new Zigly center features and offers comprehensive veterinary services
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
